

Conflict of Interest Statement

The Association for European Genomic Medicine Consortium (EGMEDC)

Adopted by the Board on 9 September 2026 pursuant to Section 7 of the Rules of Procedure for the Board - Version 1.0. This statement is a living document and will be updated as further declarations of interest are received.

Our commitment

EGMEDC is committed to transparent and accountable governance. The Board recognises that its members are active professionals in the genomic medicine field and may hold positions, ownership interests or advisory roles in organisations that interact with the Association. Such interests are not in themselves a problem; what matters is that they are disclosed, recorded and managed so that all decisions are taken in the best interests of the Association, as required by the Articles of Association and the Rules of Procedure for the Board.

Principles

In accordance with Section 7 of the Rules of Procedure for the Board, every Board Member shall promptly disclose any actual, potential or perceived conflict of interest relating to a matter considered by the Board, and shall refrain from participating in any decision on a matter in which they have a direct or indirect interest. The Board determines how each conflict is managed, and the conflict and the way it was addressed are recorded in the minutes, which are published on this website.

All Board Members submit a written declaration of interests annually and update it whenever material changes occur. The declared interests are summarised below.

Any proposed agreement between EGMEDC and a Board Member, Secretariat member, Advisory Board member, Founder, or any entity controlled by or affiliated with such persons, is approved by the disinterested Board Members only and is documented as being on arm's length, market-based terms. Any remunerated position within the Association, including Secretariat functions, requires prior Board approval with defined reporting lines, scope and budget (Rules of Procedure for the Board, Section 4.3).

Declared interests

Jens-Ole Bock, Chairman of the Board, is a 38% co-owner of and consultant to COBO Technologies ApS (DK39130327), trading as CRISPR Medicine Media and CRISPR Medicine News (CMN). This interest has been formally reviewed and acknowledged by the Board at its meeting of 22 June 2026. CMN participates in EGMEDC solely as an associated partner with a limited, Board-approved dissemination role of up to two hours per month. CMN holds no governance rights within EGMEDC, and there are no financial agreements between CMN and EGMEDC. Any future involvement of CMN in the Association's activities requires explicit approval by the disinterested Board Members in

accordance with Section 7.3 of the Rules of Procedure. The Chairman does not participate in, and does not exercise a casting vote on, any Board decision concerning CMN.

The written declarations of interest of the remaining Board Members are being collected in accordance with Section 7.4 of the Rules of Procedure and this statement will be updated once they have been received and reviewed by the Board.

Safeguards in place

Board Members serve without remuneration (Rules of Procedure for the Board, Section 10.1). Financial contributions from sponsors and industry partners do not provide any influence over the scientific positions, recommendations, governance decisions, Board resolutions or policy positions of EGMEDC (Section 6.5). The Association's finances are governed by a Board-approved annual budget; every financial transaction must be approved by two Board Members appointed by the Board for a twelve-month period, and expenditures outside the approved budget above EUR 2,500 require prior Board approval. EGMEDC funds are held in the Association's own bank account under these dual-signatory controls. Board decisions require a quorum of more than half of the Board Members and are passed by simple majority. From April 2028, at least two-thirds of the Board must be non-profit members, as laid down in Section 8 of the Articles of Association.

The Articles of Association, the Rules of Procedure for the Board and the Rules of Procedure for the Secretariat are published on this website.

Questions and reporting

This statement is reviewed by the Board at least once a year, alongside the annual review of the Rules of Procedure, and whenever a Board Member's declared interests change materially. Questions or concerns regarding conflicts of interest may be directed to the EGMEDC Secretariat at secretariat@egmedc.eu. All correspondence is logged and brought to the attention of the appropriate Board Members.